ICF syndrome

ICF syndrome (Immunodeficiency, Centromeric instability, and Facial anomalies syndrome) is a rare autosomal recessive primary immunodeficiency disorder characterized by the triad of hypogammaglobulinemia, centromeric instability of chromosomes 1, 9, and 16, and distinctive facial features. The syndrome was first described in the 1970s and is caused most commonly by mutations in the DNMT3B gene (ICF1, accounting for approximately 50-60% of cases), with additional subtypes caused by mutations in ZBTB24 (ICF2), CDCA7 (ICF3), and HELLS (ICF4). These genes are all involved in DNA methylation or chromatin remodeling, and their dysfunction leads to hypomethylation of pericentromeric satellite DNA, resulting in chromosomal instability. The immunodeficiency is the most clinically significant feature and typically presents in infancy or early childhood with recurrent and severe infections, particularly of the respiratory and gastrointestinal tracts. Most patients have markedly reduced serum immunoglobulin levels (agammaglobulinemia or hypogammaglobulinemia), though T-cell defects may also be present. Facial dysmorphism is usually mild and may include hypertelorism, flat nasal bridge, epicanthal folds, low-set ears, and macroglossia. Additional features can include intellectual disability, failure to thrive, and in some cases, congenital malformations. Treatment is primarily supportive and focuses on managing the immunodeficiency. Immunoglobulin replacement therapy (intravenous or subcutaneous) is the mainstay of treatment and can significantly reduce the frequency and severity of infections. Prophylactic antibiotics may also be used. Hematopoietic stem cell transplantation (HSCT) has been attempted in some severe cases with variable outcomes. Despite treatment, the prognosis can be guarded, as many patients succumb to severe infections or complications in childhood or early adulthood, though survival into adulthood has been reported with appropriate management.

Common questions about ICF syndrome